Traws Pharma, Inc.
TRAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001130598
No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Traws Pharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Traws Pharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Pauza Charles David | Chief Science Officer Virology | 115,971 | Jul 16, 2026 | 4 |
| Cautreels Werner | Director | 109,222 | Jul 15, 2026 | 4 |
| Savchuk Nikolay | Chief Operating Officer | 150,606 | Jul 15, 2026 | 4 |
| Stover Jack E | Director | 6,165 | Jul 14, 2026 | 4 |
| Dukes Iain D. | Chief Executive Officer | 171,130 | Jul 14, 2026 | 4 |
| Redfield Robert | Chief Medical Officer | 113,919 | Jul 14, 2026 | 4 |
| Parker Charles Nolan | Chief Financial Officer | 15,393 | Jul 14, 2026 | 2 |
| Shoemaker Mary Teresa | Director | 6,292 | Jul 14, 2026 | 4 |
| Clarke Trafford | Director | 6,157 | Jul 14, 2026 | 4 |
| Leaman John Harold | Director | 4,058 | Jul 14, 2026 | 5 |
| OrbiMed Advisors LLC | 10% Owner | 1,203,250Indirect | Apr 28, 2026 | 1 |
| OrbiMed Capital GP VIII LLC | 10% Owner | 1,203,250Indirect | Apr 28, 2026 | 1 |
| Tpav, LLC | 10% Owner | 0 | Apr 8, 2025 | 0 |
| Guerin Mark Patrick | Chief Financial Officer | 39,255 | Feb 10, 2025 | 0 |
| Greenwood Luba | Director | – | Sep 17, 2024 | 0 |
| Fruchtman Steven M | PRESIDENT, CHIEF EXECUTIVE OFF | 74,792 | Mar 15, 2024 | 0 |
| Moyo Victor M | CHIEF MEDICAL OFFICER | – | Oct 27, 2023 | 0 |
| Marino James J | Director | 21,334 | Aug 14, 2023 | 0 |
| Groopman Jerome | Director | – | Aug 14, 2023 | 0 |
| Mehta Viren | Director | – | Aug 14, 2023 | 0 |
| Atadja Peter | Director | – | Aug 14, 2023 | 0 |
| Gelder Mark S. MD | CHIEF MEDICAL OFFICER | 10,487 | Mar 14, 2023 | 0 |
| Oler Abraham N. | SVP Corp Dev & Gen Counsel | 24,514 | Feb 9, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 28, 2021 (view filing) | Sep 28 | Same day | Marino James JDirector | PPurchase | +5.95K | $4.20 | +$25.0K | +38.7%21.3K after | |
| Sep 28, 2021 (view filing) | Sep 28 | Same day | Fruchtman Steven MPresident, Chief Executive Off | PPurchase | +2.38K | $4.20 | +$10.0K | +15.1%18.1K after | |
| Sep 29, 2021 (view filing) | Sep 28 | 1 day | Gelder Mark S. MDChief Medical Officer | PPurchase | +2.38K | $4.20 | +$10.0K | New position2.38K after | |
| Sep 29, 2021 (view filing) | Sep 28 | 1 day | Oler Abraham N.SVP Corp Dev & Gen Counsel | PPurchase | +2.38K | $4.20 | +$10.0K | +23.5%12.5K after | |
| Nov 23, 2021 (view filing) | Nov 19 | 4 days | Oler Abraham N.SVP CORP DEV & GEN COUNSEL | PPurchase | +1.00K | $3.16 | +$3.16K | +5.7%18.5K after | |
| Jan 10, 2022 (view filing) | Jan 7 | 3 days | Oler Abraham N.SVP Corp Dev & Gen Counsel | PPurchase | +1.50K | $2.39 | +$3.58K | +8.1%20.0K after | |
| Jan 18, 2022 (view filing) | Jan 14 | 4 days | Oler Abraham N.SVP CORP DEV & GEN COUNSEL | PPurchase | +1.50K | $2.20 | +$3.30K | +7.5%21.5K after | |
| Jan 24, 2022 (view filing) | Jan 21 | 3 days | Oler Abraham N.SVP Corp Dev & Gen Counsel | PPurchase | +1.50K | $2.02 | +$3.03K | +7.0%23.0K after | |
| Jan 31, 2022 (view filing) | Jan 28 | 3 days | Oler Abraham N.SVP Corp Dev & Gen Counsel | PPurchase | +1.50K | $1.67 | +$2.50K | +6.5%24.5K after | |
| Jan 27, 2025 (view filing) | Dec 29, 2024 | 29 daysLate | Savchuk NikolayChief Operating Officer | PPurchase | +192.7K | – | – | –96.3K after | Derivative2 lots |
| Jan 27, 2025 (view filing) | Dec 29, 2024 | 29 daysLate | Tpav, LLC10% Owner | PPurchase | +192.7K | – | – | –96.3K after | Derivative2 lotsDuplicate filing |
| Jan 27, 2025 (view filing) | Dec 29, 2024 | 29 daysLate | Cautreels WernerChief Executive Officer | PPurchase | +192.7K | – | – | –96.3K after | Derivative2 lotsDuplicate filing |
| Jan 27, 2025 (view filing)7:03 PM ET | Dec 29, 2024 | 29 daysLate | OrbiMed Advisors LLC and 1 other10% Owner | PPurchase | +192.7K | – | – | –96.3K after | Derivative2 lotsDuplicate filing |
| Apr 28, 2026 (view filing)9:41 PM ET | Apr 16 | 12 daysLate | OrbiMed Advisors LLC and 1 other10% Owner | PPurchase | +597.7K | $1.67 | +$998.2K | +98.7%1.20M after | |
| Apr 28, 2026 (view filing)9:41 PM ET | Apr 16 | 12 daysLate | OrbiMed Advisors LLC and 1 other10% Owner | PPurchase | +2.99M | – | – | –1.79M after | Derivative3 lots |